492 related articles for article (PubMed ID: 33836637)
1. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
[TBL] [Abstract][Full Text] [Related]
2. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
[TBL] [Abstract][Full Text] [Related]
3. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
Vachiéry JL; Galiè N; Barberá JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Blair C; Miller KL; Langley J; Rubin LJ;
J Heart Lung Transplant; 2019 Feb; 38(2):194-202. PubMed ID: 30522722
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Ruopp NF; Cockrill BA
JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
[TBL] [Abstract][Full Text] [Related]
5. A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
[TBL] [Abstract][Full Text] [Related]
6. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
7. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
8. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
Abston E; Hon S; Lawrence R; Berman J; Govender P; Farber HW
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):234-238. PubMed ID: 33093789
[TBL] [Abstract][Full Text] [Related]
9. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary Arterial Hypertension: Pathophysiology and Treatment.
Lan NSH; Massam BD; Kulkarni SS; Lang CC
Diseases; 2018 May; 6(2):. PubMed ID: 29772649
[TBL] [Abstract][Full Text] [Related]
11. Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.
Hatano M; Abe K; Koike G; Takahashi T; Tunmer G; Kiely DG
Int Heart J; 2022; 63(1):99-105. PubMed ID: 35095084
[TBL] [Abstract][Full Text] [Related]
12. Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.
Zheng W; Wang Z; Jiang X; Zhao Q; Shen J
J Med Chem; 2020 Dec; 63(24):15153-15186. PubMed ID: 33314936
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
Issapour A; Frank B; Crook S; Hite MD; Dorn ML; Rosenzweig EB; Ivy DD; Krishnan US
Pediatr Pulmonol; 2022 Mar; 57(3):724-733. PubMed ID: 34921523
[TBL] [Abstract][Full Text] [Related]
14. Ambrisentan: a review of its use in pulmonary arterial hypertension.
Rivera-Lebron BN; Risbano MG
Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
[TBL] [Abstract][Full Text] [Related]
15. Management of Pulmonary Arterial Hypertension.
Weatherald J; Varughese RA; Liu J; Humbert M
Semin Respir Crit Care Med; 2023 Dec; 44(6):746-761. PubMed ID: 37369218
[TBL] [Abstract][Full Text] [Related]
16. Medical therapies for pulmonary arterial hypertension.
Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil.
Escribano Subías P; Aurtenetxe Pérez A; Pérez Olivares C; Gómez Climent L; Diago Cabezudo JI; Perelló MF
Expert Rev Respir Med; 2021 Apr; 15(4):493-504. PubMed ID: 33472458
[TBL] [Abstract][Full Text] [Related]
18. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
[TBL] [Abstract][Full Text] [Related]
19. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases.
Smukowska-Gorynia A; Gościniak W; Woźniak P; Iwańczyk S; Jaxa-Kwiatkowska K; Sławek-Szmyt S; Janus M; Paluszkiewicz J; Mularek-Kubzdela T
Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
